IP Verse

Method For Producing A Bortezomib Ester Solution - EP3324936

The patent EP3324936 was granted to Stada Arzneimittel on Sep 28, 2022. The application was originally filed on Jul 21, 2016 under application number EP16742280A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3324936

STADA ARZNEIMITTEL
Application Number
EP16742280A
Filing Date
Jul 21, 2016
Status
Granted And Under Opposition
Aug 26, 2022
Grant Date
Sep 28, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ACCORD HEALTHCAREJun 28, 2023TER MEER STEINMEISTER & PARTNERADMISSIBLE
EXTROVISJun 27, 2023BREUERADMISSIBLE
NEDERLANDSCH OCTROOIBUREAUJun 27, 2023NEDERLANDSCH OCTROOIBUREAUADMISSIBLE
STRAWMANJun 26, 2023VOSSIUS & PARTNER PATENTANWALTE RECHTSANWALTE MBBWITHDRAWN
GRUNDJun 16, 2023GRUNDADMISSIBLE
CONSILIENT HEALTHApr 24, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (31) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
EXAMINATIONCN103070835
INTERNATIONAL-SEARCH-REPORTEP2644189
INTERNATIONAL-SEARCH-REPORTWO2013128419
INTERNATIONAL-SEARCH-REPORTWO2015025000
OPPOSITIONCN103044468
OPPOSITIONCN103070835
OPPOSITIONEA021179
OPPOSITIONEP2251344
OPPOSITIONEP2644189
OPPOSITIONEP3324937
OPPOSITIONIN3324DELNP2012
OPPOSITIONUS2004054012
OPPOSITIONUS2011039939
OPPOSITIONUS2011178470
OPPOSITIONUS2913386
OPPOSITIONUS5780454
OPPOSITIONUS6713446
OPPOSITIONWO02059130
OPPOSITIONWO03041687
OPPOSITIONWO2008135601
OPPOSITIONWO2009124586
OPPOSITIONWO2009154737
OPPOSITIONWO2010121762
OPPOSITIONWO2011116286
OPPOSITIONWO2012047845
OPPOSITIONWO2012121523
OPPOSITIONWO2013128419
OPPOSITIONWO2014023647
OPPOSITIONWO2015025000
OPPOSITIONWO2017013209
OTHERCN103070835

Non-Patent Literature (NPL) Citations (64) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
EXAMINATION- I Butler ET AL, "Removal of dissolved oxygen from water: A comparison of four common techniques", TALANTA, NL, (19940201), vol. 41, no. 2, doi:10.1016/0039-9140(94)80110-X, ISSN 0039-9140, pages 211 - 215, XP055449254
OPPOSITION- Anonym, "Gebrauchsinformation: Information für den Anwender VELCADE" 3,5 mg Pulver zur Herstellung einer Injektionslösung Bortezomib", (20140101), pages 1 - 13, XP093049075
OPPOSITION- Anonymous, "APPROVED DRUG PRODUCTS With Therapeutic Equivalence Evaluations The "Orange Book"", APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS, (20051231), pages 1 - 7, XP093162960
OPPOSITION- Anonymous, "Assessment report VELCADE", European Medicines Agency, (20120621), pages 1 - 58, XP093162940
OPPOSITION- Anonymous, "Bortezomib STADA® 2,5 mg/ml Injektionslösung Fachinformation", STADAPHARM, (20210601), pages 1 - 20, XP055956152
OPPOSITION- Anonymous, "DISSOLVED OXYGEN FACT-SHEET, 2004", The Clean Water Team Guidance Compendium for Watershed Monitoring and Assessment State Water Resources Control Board, (20040929), pages 1 - 5, The Clean Water Team Guidance Compendium for Watershed Monitoring and Assessment State Water Resources Control Board, URL: https://www.waterboards.ca.gov/water_issues/programs/swamp/docs/cwt/guidance/3110en.pdf, XP093165296
OPPOSITION- Anonymous, "European Medicines Agency", European Medicines Agency, (20030801), pages 1 - 20, European Medicines Agency, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-1-r2-stability-testing-new-drug-substances-and-products-step-5_en.pdf, XP093162975
OPPOSITION- Anonymous, "Gebrauchsfertig Übersetzung / Definition", TheFreeDictionary, (20090101), pages 1 - 2, TheFreeDictionary, URL: https://de.thefreedictionary.com/gebrauchsfertig, (20240208), XP093129246
OPPOSITION- Anonymous, "Gebrauchsinformation: Information für den Anwender VELCADE" 3,5 mg Pulver zur Herstellung einer Injektionslösung Bortezomib", (20140101), pages 1 - 13, XP093049075
OPPOSITION- Anonymous, "Geschäftsbericht 2019 ", Geschäftsbericht 2019, STADA Arzneimittel AG, (20190101), pages 1 - 169, Geschäftsbericht 2019 , URL: https://www.stada.com/media/5545/gj2019-geschaeftsbericht-stada.pdf, XP093262375
OPPOSITION- Anonymous, "GUIDELINE ON STABILITY TESTING: STABILITY TESTING OF EXISTING ACTIVE SUBSTANCES AND RELATED FINISHED PRODUCTS", European Medicines Agency Inspections, (20031217), European Medicines Agency Inspections, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf, (20240301), XP093136629
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION VELCADE (bortezomib) for Injection", (20141001), pages 1 - 38, XP093062939
OPPOSITION- Anonymous, "HIGHLIGHTS OF PRESCRIBING INFORMATION Velcade", USFDA, (20030101), pages 1 - 38, XP093162948
OPPOSITION- Anonymous, "ICH guideline Q3C (R8) on impurities: guideline for residual solvents - Step 5", European Medicines Agency (EMA), (20221125), European Medicines Agency (EMA), URL: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ich-guideline-q3c-r8-impurities-guideline-residual-solvents-step-5_en.pdf, (20240301), XP093136693
OPPOSITION- Anonymous, "Instruction manual InPro 6000 G Series", Instruction manual InPro 6000 G Series, METTLER TOLEDO, (20230301), pages 1 - 132, Instruction manual InPro 6000 G Series, URL: https://www.mt.com/dam/non-indexed/po/pro/pdf/ba/52206477_F_IM_GPO_InPro6000_Series_3lang_2023_03_LR.pdf, (20240208), XP093129285
OPPOSITION- Anonymous, "Manual "1302 Microcathode Oxygen Electrodes"", Manual "1302 Microcathode Oxygen Electrodes", Strathkelvin Instruments, (20110101), pages 1 - 14, Manual "1302 Microcathode Oxygen Electrodes", URL: https://www.strathkelvin.com/wp-content/uploads/2015/04/electrode-manual.pdf, (20240208), XP093129287
OPPOSITION- Anonymous, "Use of an Oxygen Extractor to Minimize Oxidation of compounded Preparations - PMID: 23985821", PMID: 23985821, (19991201), pages 1 - 1, PMID: 23985821, URL: https://pubmed.ncbi.nlm.nih.gov/23985821/, XP093165304
OPPOSITION- Anonymous, "VELCADE ® 1 mg /-3,5 mg Pulver zur Herstellung einer Injektionslösung - Bortezomib - GEBRAUCHSINFORMATION: INFORMATION FÜR DEN ANWENDER", (20120301), URL: https://shop.ried-apotheken.de/images/ecommerce/00/82/00822831_2017-07_de_s.pdf, XP093195761
OPPOSITION- Anonymous, "VELCADE (bortezomib) for Injection PRESCRIBING INFORMATION", Millennium Pharmaceuticals, Inc, (20060301), pages 1 - 29, XP093049079
OPPOSITION- Anonymous, "Velcade : EPAR - Scientific Discussion - European Medicines Agency ", Scientific Discussion, European Medicines Agency, (20040501), pages 1 - 42, Scientific Discussion, URL: https://www.ema.europa.eu/en/documents/scientific-discussion/velcade-epar-scientific-discussion_en.pdf, (20240208), XP093129249
OPPOSITION- Anonymous, "Velcade, Procedural steps taken and scientific information after the authorisation", Procedural steps taken and scientific information after the authorisation, European Medicines Agency, (20240101), pages 1 - 36, Procedural steps taken and scientific information after the authorisation, URL: https://www.ema.europa.eu/en/documents/procedural-steps-after/velcade-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf, XP093262372
OPPOSITION- Banker Gilbert S, Et Al, "Modern Pharmaceutics. Fourth Ed.", CRC Press, (20220101), pages 591 - 591, XP093062928
OPPOSITION- Bolognese Adele, Et Al, "An NMR Study of the Bortezomib Degradation under Clinical Use Conditions", Advances in Hematology, (20090101), no. e 704928, pages 1 - 5, XP093049061
OPPOSITION- Bolognese Adele, Et Al, "An NMR Study of the Bortezomib Degradation under Clinical Use Conditions", Advances in Hematology, (20090101), vol. e 704928, pages 1 - 5, XP093049061
OPPOSITION- Bouwman-Boer Yvonne, Practical Pharmaceutics. An International Guide for the preparation, care and use of medicinal products. Excerpt, (20150901), pages 281 - 281, ISBN 978-3-319-15813-6, XP093062916
OPPOSITION- Brazeau Gayle A, Et Al, "Encyclopedia of Pharmaceutical Technology. Excerpts", (20070101), vol. 1, pages 1 - 36, XP093058361
OPPOSITION- Broadhead J, Gibson, M, "Chapter 9: Parenteral Dosage Forms", Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, CRC Press, (20090101), vol. 199, pages 325 - 347, XP055882149
OPPOSITION- C. Hunnius, "Wasserstoffionenkonzentration", Pharmazeutisches Wörterbuch, Walter de Gruyter, (19750101), pages 742 - 743, ISBN 3-11-001631-1, XP009551929
OPPOSITION- D86 - BORTEZOMIB STABILITY STUDY REPORT (DATED 23 OCTOBER 2024)
OPPOSITION- Dash Alekha K, Et Al, Pharmaceutics - Basic Principles and Application to Pharmacy Practice, (20131001), pages 212 - 212, ISBN 978-0-12-386890-9, XP093062921
OPPOSITION- Ema, "VELCADE 1 mg powder for solution for injection. VELCADE® - SmPC (EU/1/04/274) ", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, pages 1 - 51, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, (20240123), XP093122558
OPPOSITION- EMEA, "Guideline on Stability Testing: Stability testing of Existing Active Substances and Related Finished Products", no. CPMP/QWP/122/02.REV 1, pages 1 - 18, URL: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-stability-testing-stability-testing-existing-active-substances-and-related-finished-products-revision-1-corr_en.pdf, (20080626), XP002662653
OPPOSITION- European Medicines Agency, "Assessment Report VELCADE. CHMP EMA/432973/2012", (20120621), pages 1 - 58, XP093062935
OPPOSITION- Fda, "Guide To Inspections Of Lyophilization Of Parenterals (7/93)", US FDA, (20141111), US FDA, URL: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides/lyophilization-parenteral-793, (20210712), XP055823148
OPPOSITION- Florence A T, Et Al, "Modern Pharmaceutics. Basic Principles and Systems", (20100101), vol. 1, pages 579 - 579, XP093062924
OPPOSITION- Jain Sanjai K, Et Al, Bentley's Textbook of Pharmaceutics, Elsevier, (20110101), pages 414 - 414, XP093062918
OPPOSITION- Janssen-Cilag International Nv, "VELCADE 3.5 mg powder for solution for injection", ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, European Medicines Agency, (20210604), pages 32 - 64, ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS, URL: https://www.ema.europa.eu/en/documents/product-information/velcade-epar-product-information_en.pdf, (20240208), XP093129243
OPPOSITION- Michael J Akers, "Parenteral Preparations", (20130301), pages 495 - 532, Sample chapter from Remington: Essentials of Pharmaceutics, URL: http://www.pharmpress.com/files/docs/Remington_Ch_26.pdf, (20151022), XP055222827
OPPOSITION- Michael J Akers, "Parenteral Preparations", Sample chapter from Remington: Essentials of Pharmaceutics, (20130301), pages 495 - 532, Sample chapter from Remington: Essentials of Pharmaceutics, URL: http://www.pharmpress.com/files/docs/Remington_Ch_26.pdf, (20151022), XP055222827
OPPOSITION- Michael J. Akers, PhD, "Chapter 26 : Parenteral Preparations 495 ", Remington Essentials of Pharmaceutics, GB, Pharmaceutical Press, (20120101), pages 495 - 531, ISBN 9780857111050, XP009554144
OPPOSITION- Rojas F Sánchez, Berruezo García J, Espinosa Bosch M, Bosch Ojeda C, "CHEMICAL STABILITY OF BORTEZOMIB SOLUTIONS IN ORIGINAL MANUFACTURER VIAL AT ROOM TEMPERATURE AND IN SYRINGE AT 4 0 C", International Journal of Pharmacy and Biological Sciences, (20130101), vol. 3, no. 1, ISSN 2230-7605, pages 449 - 458, XP093129271
OPPOSITION- Rowe et al, "Mannitol", Handbook of Pharmaceutical Excipients, 7th edn., Pharmaceutical Press, (20120101), pages 479 - 482, Handbook of Pharmaceutical Excipients, 7th edn., URL: https://www.pharmpress.com/files/docs/Excipients7e_samplemonos(1).pdf, (20190318), XP002789781
OPPOSITION- Swarbrick J (ed.), "Encyclopedia of Pharmaceutical Technology. Third Edition. Excerpts", Pharmaceutical Press, (20070101), vol. 1, pages 1 - 36, XP093061501
OPPOSITION- Voigt Rudolf, "Kapitel 20: Injektions- und Infusionszubereitungen", Voigt Rudolf, Voigt Rudolf, Pharmazeutische Technologie : für Studium und Beruf ; mit 109 Tabellen, Stuttgart, DE , Dt. Apotheker-Verl. , (20060101), pages 459 - 494, ISBN 978-3-7692-3511-1, XP093049534
OPPOSITION- Voigt Rudolf, "Pharmazeutische Technologie für Studium und Beruf. Kapitel 20: Injektions- und Infusionszubereitungen", Voigt Rudolf, Voigt Rudolf, Pharmazeutische Technologie : fur Studium und Beruf ; mit 109 Tabellen, Stuttgart, DE , Dt. Apotheker-Verl. , (20060101), pages 459 - 494, ISBN 978-3-7692-3511-1, XP093058371
OPPOSITION- "Wirkstoffhaltige Kaugummis - Parenteralia", Anonymous, Europäisches Arzneibuch, 8. Ausgabe, Grundwerk; Band 1 Allgemeiner Teil MONOGRAPHIEGRUPPEN, DE, Govi-Verlag - Pharmazeutischer Verlag / Deutscher Apotheker Verlag, (20140101), pages 1196 - 1199, ISBN 978-3-7692-6253-7, XP009553776
OPPOSITION- WU S, WAUGH W, STELLA V J, "Degradation pathways of a peptide boronic acid derivative, 2-Pyz-(CO)-Phe-Leu-B(OH)(2)", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20000601), vol. 89, no. 06, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, ISSN 0022-3549, pages 758 - 765, XP001197158
OPPOSITION- WU S, WAUGH W, STELLA V J, "Degradation Pathways of a Peptide Boronic Acid Derivative, 2‐Pyz‐(CO)‐Phe‐Leu‐B(OH)2", Journal of Pharmaceutical Sciences, American Chemical Society and American Pharmaceutical Association, US, US , (20000601), vol. 89, no. 06, doi:10.1002/(SICI)1520-6017(200006)89:6<758::AID-JPS7>3.0.CO;2-L, ISSN 0022-3549, pages 758 - 765, XP001197158
OPPOSITION- I Butler et al, "Removal of dissolved oxygen from water: A comparison of four common techniques", TALANTA, NL , (19940201), vol. 41, no. 2, doi:10.1016/0039-9140(94)80110-X, ISSN 0039-9140, pages 211 - 215, XP055449254
OPPOSITION- I Butler, ', Martin A A Schoonen ', David T Rickard ', "Removal of dissolved oxygen from water: A comparison of four common techniques", TALANTA, ELSEVIER, AMSTERDAM, NL, NL , (19940201), vol. 41, no. 2, doi:10.1016/0039-9140(94)80110-X, ISSN 0039-9140, pages 211 - 215, XP055449254
OPPOSITION- I Butler, ', Martin A A Schoonen ', David T Rickard ', "Removal of dissolved oxygen from water: A comparison of four common techniques", TALANTA, NL , (19940201), vol. 41, no. 2, doi:10.1016/0039-9140(94)80110-X, ISSN 0039-9140, pages 211 - 215, XP055449254
OPPOSITION- Butler Ian, Schoonen Martin A A, Rickard David, "Removal of Dissolved Oxygen from Water: A Comparison of Four Common Techniques Framboids View project Chemistry of surfaces and nanoparticles View project", Talanta, Vol 41 (2), doi:10.1016/0039-9140(94)80110-X·Source:, (19940101), pages 211 - 215, Talanta, Vol 41 (2), URL: https://engage.aiche.org/HigherLogic/System/DownloadDocumentFile.ashx?DocumentFileKey=6a7d3287-6ce9-470a-a7da-c13b91c65357&ssopc=1, (20220408), XP055911058
OPPOSITION- R.J. FERRIER, "Carbohydrate Boronates", Advances in Carbohydrate Chemistry and Biochemistry, (19780000), vol. 35, doi:10.1016/S0065-2318(08)60218-8, pages 31 - 80, XP055335949
OPPOSITION- Robert J. Ferrier, "Carbohydrate boronates", Advances in Carbohydrate Chemistry and Biochemistry , (19780101), pages 31 - 80, doi:10.1016/S0065-2318(08)60218-8, XP055335949
OPPOSITION- Navneeta Rajan, Habermehl Jason, Coté Marie-France, Doillon Charles J, Mantovani Diego, "Preparation of ready-to-use, storable and reconstituted type I collagen from rat tail tendon for tissue engineering applications", Nature Protocols, vol. 1, n. 6, doi:10.1038/nprot.2006.430, (20061201), pages 2753 - 2758, Nature Protocols, vol. 1, n. 6, URL: https://www.nature.com/articles/nprot.2006.430.pdf, (20200625), XP055708674
OPPOSITION- Akers Micheal J, "Drug Delivery: Prenteral Route ", Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare , (20070101), pages 1266 - 1287, doi:10.1081/E-EPT-100000368, XP093087574
OPPOSITION- Brazeau Gayle A, Adam Persky , Jintana Napaporn , "Dosage Forms: Parenterals", Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare , (20070101), pages 1 - 13, doi:10.1081/E-EPT-100001047, XP093087572
OPPOSITION- Templeton Allen C, Robert A. Reed, "Headspace Oxygen Analysis in Pharmaceutical Products", Encyclopedia of Pharmaceutical Technology Third Edition Volume 1, Informa Healthcare, (20070101), pages 1967 - 1976, doi:10.1081/E-EPT-120016552, XP093087576
OPPOSITION- WATERMAN et al., "Stabilization of Pharmaceuticals to Oxidative Degradation", Pharmaceutical Development and Technology, (20020000), vol. 7, no. 1, doi:10.1081/PDT-120002237, pages 1 - 32, XP009051878
OPPOSITION- Carati Daniela, Masini Carla, Minguzzi Martina, Petocchi Benedetta, Romanazzi Cristiana, Rondoni Cristina, Sangiorgi Elisa, Sferra Stella, Simonetta Sara, Stancari Alessandra, Locchi Federica, Zanardi Alessandra, "Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4°C and room temperature", European journal of hospital pharmacy : EJHP, London : BMJ Group, (20121001), vol. 19, no. 5, doi:10.1136/ejhpharm-2011-000041, ISSN 2047-9956, pages 428 - 431, XP009551928
OPPOSITION- Bolognese Adele, Esposito Anna, Manfra Michele, Catalano Lucio, Petruzziello Fara, Martorelli Maria Carmen, Pagliuca Raffaella, Mazzarelli Vittoria, Ottiero Maria, Scalfaro Melania, Rotoli Bruno, "An NMR Study of the Bortezomib Degradation under Clinical Use Conditions", Advances in Hematology, Hindawi Publishing Corporation, (20090414), vol. 2009, doi:10.1155/2009/704928, ISSN 1687-9104, pages 1 - 5, XP093129221
OPPOSITION- WALKER et al., "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C", Canadian Society Of Hospital Pharmacy, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, XP008113111
OPPOSITION- Walker S E; Milliken D; Law S, "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C)", Canadian society of hospital pharmacy, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, ISSN 0008-4123, pages 14 - 20, XP008113111
OPPOSITION- Walker S E; Milliken D; Law S, "Stability of bortezomib reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C)", CANADIAN SOCIETY OF HOSPITAL PHARMACY, CANADIAN SOCIETY OF HOSPITAL PHARMACISTS, OTTAWA, (20080101), vol. 61, no. 1, doi:10.4212/cjhp.v61i1.6, ISSN 0008-4123, pages 14 - 20, XP008113111

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents